The global aptamer
market was valued at approximately US$ 1.0 Bn in 2016 is projected to
register cumulative annual growth rate (CAGR) of over 20.0% from 2017
to 2025, according to a new report published by Transparency Market
Research (TMR) titled “Aptamer Market – Global Industry
Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025”.
The report suggests that surge in interest of research activity in
the field of aptamer technology is likely to spur the demand of
aptamer in the coming years (2017 to 2025). As key players introduce
their new aptamer services for different application in developed
markets such a North America and Western Europe, these regions are
likely to account for dominating share of the global aptamer market.
Demands for new diagnostic assay and increasing research activity in
emerging markets such as China and Japan is likely to boost growth of
Asia Pacific aptamer market at a CAGR of around 21.0% from 2017 to
2025.
Request for
Sample Copy of Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1335
Aptamer can be used
as alternative to antibodies for various application. There is no
formal regulatory guideline, which specifically addresses the quality
expectation of aptamers. The regulatory expectation of aptamer-based
drugs is still evolving. Several countries in Europe have tedious
documentation processes for starting clinical trials of aptamers. For
example, in Europe, the EU Clinical Trial Directive 2001/20/ EC is
mandatory for initiation of aptamer clinical trials. However, the
region has not developed any oligonucleotide specific guideline that
can address the general requirements for the quality of aptamer
clinical trials. Moreover, lack of universal rules for the
application of aptamers in bioassays, which is well established when
working with antibodies, restrains growth of global aptamer market.
The report offers
detailed segmentation of global aptamers market based on material
type, selection technique and applications. Among the selection
technique studied, SELEX technique segment is poised to account for
leading share of the global market during the forecast period from
2017 to 2025. SELEX technique is likely to get boost for the
modification of existing SELEX process, and available of the new
updated SELEX technique like CE-SELEX, M- SELEX etc. which overcome
the certain limitation for aptamer selection. The other technique
(X-aptamer, MARAS technique etc.) segment is anticipated to lose its
market share during the forecast period, and is expected to hold a
share of ~18.0% by 2025 from ~21% in 2016. Availability of upgraded
SELEX technique and lack of selection of high affinity ligands as
compare to SELEX technique are factors likely to hamper this
segment.
Enquiry for
discount on this report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1335
Among applications,
research segment is projected to hold dominant share of global
aptamer market during the forecast period and is likely to expand at
CAGR more than 21.0% from 2017 to 2025. Major factors responsible for
the dominance of this segment are efforts by several key players to
develop new aptamers for research and development applications. For
example, Aptagen, LLC has developed aptabodies (patent pending) that
overcome the limitation of traditional pharmaceutical drug discovery
process. The Aptabody technology demands shorter development time and
offers effective Adsorption, Distribution, Metabolism and Excretion
(ADME) properties due to unique chemical properties. Aptabodies are
formed by hybridization of two DNA aptamers and allow detection of
human thrombin effectively compared to traditional aptamers. In
addition, aptabodies represent new area of development for next
generation pharmaceuticals with improved pharmacokinetics and
pharmacodynamic. Diagnostics segment, accounted for more than 30.0%
share of global aptamer market in 2016, in terms of value. It is
anticipated to have substantial growth and account for approximately
33.8% of market share by 2025.
In terms of value,
North America was leading contributor in global aptamer market in
2016. High level of research activity in the U.S. is one of the
contributing factor for major share of the North America market.
Furthermore, presence of several key players such as Aptagen, Inc.,
Regado Biosciences, Inc. and Somalogic, Inc. has resulted in
increased investment in research and development of novel aptamers.
Thus, presence of these players would help the aptamers market in
North America to grow rapidly during the forecast period
Pharmaceutical research and development spending in emerging markets
such as China and India are rising, which is fueling the expansion of
Asia Pacific aptamer market. Regaining economic growth in Latin
American markets such as Brazil is augmenting research and
development activity, spending is increasing in diagnosis and
treatment of various diseases in this region. This factor is likely
to propel Latin America cardiovascular drugs market at CAGR of 19.0%
from 2017 to 2025.
Report Overview @
https://www.transparencymarketresearch.com/aptamers-market.html
The report also
provide profiles of leading players operating in global aptamer
market include AM Biotech, Aptagen, LLC., Aptamer Group, Aptamer
Sciences, Inc., Base Pair Biotechnologies, CD Genomics, NeoVentures
Biotechnology Inc., NAXXON Pharma, Aptus Biotech, TriLink
BioTechnologies, LLC., and Pfizer Inc. Expansion of aptamer based
products portfolio through improving existing drugs and developing
new drug molecules is one of the key strategy adopted by many key
players, recent developing drugs such as NOX-E36 for treating type 2
diabetes by NAXXON Pharma and other key players reflect these
strategies.
About Us
Transparency Market
Research (TMR) is a market intelligence company, providing global
business information reports and services. Our exclusive blend of
quantitative forecasting and trends analysis provides forward-looking
insight for thousands of decision makers. TMR’s experienced team of
analysts, researchers, and consultants, use proprietary data sources
and various tools and techniques to gather, and analyze information.
Our business offerings represent the latest and the most reliable
information indispensable for businesses to sustain a competitive
edge.
Each TMR syndicated
research report covers a different sector - such as pharmaceuticals,
chemicals, energy, food & beverages, semiconductors, med-devices,
consumer goods and technology. These reports provide in-depth
analysis and deep segmentation to possible micro levels. With wider
scope and stratified research methodology, TMR’s syndicated reports
strive to provide clients to serve their overall research
requirement.
US Office
Contact
90 State Street,
Suite 700
Albany, NY 12207
Tel:
+1-518-618-1030
USA - Canada Toll
Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment